PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial

Introduction: Addressing the Unmet Need in ALS

Amyotrophic lateral sclerosis (ALS) remains one of the most challenging frontiers in clinical neurology. Characterized by the progressive degeneration of upper and lower motor neurons, this fatal disease typically leads to respiratory failure and death within three to five years of symptom onset. Despite decades of research, the therapeutic landscape remains limited. While riluzole and edaravone offer modest survival or functional benefits, there is a critical unmet need for interventions that can meaningfully alter the disease trajectory. The PARADIGM trial, recently published in JAMA Neurology, investigates PrimeC, a novel oral combination therapy designed to address the multifactorial pathogenesis of ALS.

Highlights of the PARADIGM Trial